Germany Severe Asthma Biologics Market Industry Trends and Forecast to 2034: Segmented by (Target, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Germany · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$446.0 MnPlaceholder estimate
Estimate 2025$483.4 Mn3.3% of the global market
Projected 2034$999.0 Mn 106.7%Adds $515.6 Mn over 9 forecast years
CAGR 2025–20348.4%Faster than 61% of 180 Pharmaceuticals markets here
Key players5
Germany is 3.33% of the global market.
In Europe, the largest is Germany (this report) at $483.4 Mn.
12 in GermanySource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Germany Severe Asthma Biologics Market Analysis Executive Summary
Severe asthma biologics are injections that block immune signals driving severe asthma attacks.
Key segments of the severe Asthma Biologics market include target (IL-5, IL-4/IL-13 and IgE) and age (Children and Adults).
Germany Severe Asthma Biologics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Germany Severe Asthma Biologics Market Dynamics
Market Growth Drivers
Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the severe Asthma Biologics market.
Opportunity
Earlier screening, new drug classes and home-based care give the severe Asthma Biologics market room to grow.
Market Restraints
Late diagnosis, high prices of new medicines, limited specialist care and poor adherence hold back the severe Asthma Biologics market.
Competitive Landscape for Severe Asthma Biologics Market in Germany
The severe Asthma Biologics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Severe Asthma Biologics Market in Germany
Severe Asthma Biologics in Germany: rules, payment and research
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by BfArM or, for vaccines and blood products, the Paul-Ehrlich-Institut.[1] Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines.[2] ClinicalTrials.gov lists 12 studies on Severe Asthma Biologics that are recruiting, active or about to start in Germany.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for severe Asthma Biologics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Germany.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Target
4.2 By Age
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Sanofi
7.2 Regeneron Pharmaceuticals
7.3 AstraZeneca
7.4 GSK
7.5 Novartis
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The severe Asthma Biologics market can be segmented based on various criteria, including target, age and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Severe Asthma Biologics right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Severe Asthma Biologics in context
Germany compared
Health spending per person: 6,849 US$ per person (2024). World: 1,317 US$ per person (2023). Highest of the 6 countries we cover in Europe.[1]
Doctors: 4.53 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 6 countries we cover in Europe.[2]
People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 6 countries we cover in Europe.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
How big is the Severe Asthma Biologics market in Germany?
Placeholder estimate: about $483.4 Mn in 2025, rising to about $999.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Severe Asthma Biologics market in Germany growing?
Placeholder estimate: about 8.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Severe Asthma Biologics market report cover?
The report splits the market by target (IL-5, IL-4/IL-13, IgE, TSLP), age (Children, Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Severe Asthma Biologics market?
Key players include Sanofi, Regeneron Pharmaceuticals, AstraZeneca, GSK PLC and Novartis AG.
What is driving the Severe Asthma Biologics market?
Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the severe Asthma Biologics market.
Who regulates Severe Asthma Biologics in Germany?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by BfArM or, for vaccines and blood products, the Paul-Ehrlich-Institut. Source: Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
How is healthcare paid for in Germany?
Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines. Source: Federal Joint Committee (G-BA). Checked 14 Nov 2026.
How many clinical trials on Severe Asthma Biologics are running in Germany?
12 studies are recruiting, active or about to start in Germany, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.
How much research is published on Severe Asthma Biologics?
PubMed lists 322 papers on Severe Asthma Biologics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Germany 
Russia
US
China
Canada
Japan
Italy
Brazil
France
UK
Saudi Arabia
India
Ecuador
Mexico
Spain
Australia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Thailand
Singapore
Kenya
Pfizer Inc.